These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species. Schell WA; Jones AM; Borroto-Esoda K; Alexander BD Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827419 [TBL] [Abstract][Full Text] [Related]
6. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). Pfaller MA; Messer SA; Motyl MR; Jones RN; Castanheira M J Antimicrob Chemother; 2013 Apr; 68(4):858-63. PubMed ID: 23190764 [TBL] [Abstract][Full Text] [Related]
7. Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method. Espinel-Ingroff A; Arendrup M; Cantón E; Cordoba S; Dannaoui E; García-Rodríguez J; Gonzalez GM; Govender NP; Martin-Mazuelos E; Lackner M; Lass-Flörl C; Linares Sicilia MJ; Rodriguez-Iglesias MA; Pelaez T; Shields RK; Garcia-Effron G; Guinea J; Sanguinetti M; Turnidge J Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799206 [TBL] [Abstract][Full Text] [Related]
8. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Pfaller MA; Messer SA; Motyl MR; Jones RN; Castanheira M Antimicrob Agents Chemother; 2013 Feb; 57(2):1065-8. PubMed ID: 23229479 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method. Mesquida A; Díaz-García J; Sánchez-Carrillo C; Muñoz P; Escribano P; Guinea J Clin Microbiol Infect; 2022 Jan; 28(1):140.e1-140.e4. PubMed ID: 34619396 [TBL] [Abstract][Full Text] [Related]
12. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246 [TBL] [Abstract][Full Text] [Related]
13. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791 [TBL] [Abstract][Full Text] [Related]
14. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012. Pfaller MA; Castanheira M; Messer SA; Jones RN Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853 [TBL] [Abstract][Full Text] [Related]
15. Role of FKS Gene in the Susceptibility of Pathogenic Fungi to Echinocandins. Hori Y; Shibuya K Med Mycol J; 2018; 59(2):E31-E40. PubMed ID: 29848909 [TBL] [Abstract][Full Text] [Related]
16. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Beyda ND; Lewis RE; Garey KW Ann Pharmacother; 2012; 46(7-8):1086-96. PubMed ID: 22811350 [TBL] [Abstract][Full Text] [Related]
17. Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS). Kritikos A; Neofytos D; Khanna N; Schreiber PW; Boggian K; Bille J; Schrenzel J; Mühlethaler K; Zbinden R; Bruderer T; Goldenberger D; Pfyffer G; Conen A; Van Delden C; Zimmerli S; Sanglard D; Bachmann D; Marchetti O; Lamoth F; Clin Microbiol Infect; 2018 Nov; 24(11):1214.e1-1214.e4. PubMed ID: 29909005 [TBL] [Abstract][Full Text] [Related]
18. [In vitro activity of anidulafungin. Comparison with the activity of other echinocandins]. Martín Mazuelos E; Rodríguez-Tudela JL Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():7-13. PubMed ID: 19572429 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. Pfaller MA; Rhomberg PR; Messer SA; Castanheira M Diagn Microbiol Infect Dis; 2015 Apr; 81(4):259-63. PubMed ID: 25600842 [TBL] [Abstract][Full Text] [Related]
20. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program. Pfaller MA; Messer SA; Rhomberg PR; Castanheira M Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]